<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.2" xml:lang="ru" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="issn">2687-0940</journal-id><journal-title-group><journal-title>Challenges in modern medicine</journal-title></journal-title-group><issn pub-type="epub">2687-0940</issn></journal-meta><article-meta><article-id pub-id-type="doi">10.18413/2687-0940-2020-43-1-28-37</article-id><article-id pub-id-type="publisher-id">8</article-id><article-categories><subj-group subj-group-type="heading"><subject>INTERNAL DISEASES</subject></subj-group></article-categories><title-group><article-title>COMMUNITY-ACQUIRED PNEUMONIA IN PATIENTS WITH COPD: TEMPORARY COMORBIDITY OR RISK FACTOR FOR DEATH?</article-title><trans-title-group xml:lang="en"><trans-title>COMMUNITY-ACQUIRED PNEUMONIA IN PATIENTS WITH COPD: TEMPORARY COMORBIDITY OR RISK FACTOR FOR DEATH?</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Uryasyev</surname><given-names>O. M.</given-names></name><name xml:lang="en"><surname>Uryasyev</surname><given-names>O. M.</given-names></name></name-alternatives></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Panfilov</surname><given-names>Yu. A.</given-names></name><name xml:lang="en"><surname>Panfilov</surname><given-names>Yu. A.</given-names></name></name-alternatives><email>panfilov.rzgmu@gmail.com</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Grinkova</surname><given-names>Y. N.</given-names></name><name xml:lang="en"><surname>Grinkova</surname><given-names>Y. N.</given-names></name></name-alternatives></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Granatkin</surname><given-names>M. A.</given-names></name><name xml:lang="en"><surname>Granatkin</surname><given-names>M. A.</given-names></name></name-alternatives></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Pyko</surname><given-names>A. A.</given-names></name><name xml:lang="en"><surname>Pyko</surname><given-names>A. A.</given-names></name></name-alternatives></contrib></contrib-group><pub-date pub-type="epub"><year>2020</year></pub-date><volume>43</volume><issue>1</issue><fpage>0</fpage><lpage>0</lpage><self-uri content-type="pdf" xlink:href="/media/journal-medicine/2020/1/28-37.pdf" /><abstract xml:lang="ru"><p>At present, community-acquired pneumonia (CAP) is one of the leading places among common infectious diseases. Chronic constructive pulmonary disease is considered a risk factor for the development of community-acquired pneumonia, and numerous studies and studies on the study of community-acquired pneumonia have shown that COPD is mentioned as a concomitant pathology in 19&amp;ndash;62 % of patients with CAP. As for statistics on the development of community-acquired pneumonia in patients with exacerbation of COPD, a small number of works on this problem are currently published. Most of these studies are devoted to clinical cases with severe exacerbation of COPD (with a picture of acute respiratory failure). According to international statistics, the mortality rate of patients with chronic obstructive pulmonary disease hospitalized with exacerbation to the hospital is 8 %, a year after the relapse &amp;ndash; 23 %. If we talk about patients with acute respiratory failure amid exacerbation of COPD, then the death rate is 24 %, in patients older than 65 years &amp;ndash; 30 %.</p></abstract><trans-abstract xml:lang="en"><p>At present, community-acquired pneumonia (CAP) is one of the leading places among common infectious diseases. Chronic constructive pulmonary disease is considered a risk factor for the development of community-acquired pneumonia, and numerous studies and studies on the study of community-acquired pneumonia have shown that COPD is mentioned as a concomitant pathology in 19&amp;ndash;62 % of patients with CAP. As for statistics on the development of community-acquired pneumonia in patients with exacerbation of COPD, a small number of works on this problem are currently published. Most of these studies are devoted to clinical cases with severe exacerbation of COPD (with a picture of acute respiratory failure). According to international statistics, the mortality rate of patients with chronic obstructive pulmonary disease hospitalized with exacerbation to the hospital is 8 %, a year after the relapse &amp;ndash; 23 %. If we talk about patients with acute respiratory failure amid exacerbation of COPD, then the death rate is 24 %, in patients older than 65 years &amp;ndash; 30 %.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>community-acquired pneumonia</kwd><kwd>chronic obstructive pulmonary disease (COPD)</kwd><kwd>death risk factor</kwd></kwd-group><kwd-group xml:lang="en"><kwd>community-acquired pneumonia</kwd><kwd>chronic obstructive pulmonary disease (COPD)</kwd><kwd>death risk factor</kwd></kwd-group></article-meta></front><back><ref-list><title>Список литературы</title><ref id="B1"><mixed-citation>1. Avdeev S.N., Bajmakanova G.E., Zubairova P.A., Chuchalin A.G. 2006. Pnevmoniya kak prichina ostroj dyhatel&amp;#39;noj nedostatochnosti u bol&amp;#39;nyh HOBL [Pneumonia as a factor of acute respiratory failure in patients with COPD]. Pul&amp;#39;monologiya, 5: 115&amp;ndash;119.</mixed-citation></ref><ref id="B2"><mixed-citation>2. Bajmakova G.E., Zubairova P.A., Avdeev S.N., CHuchalin A.G. 2009. Osobennosti klinich-eskoj kartiny i techeniya vnebol&amp;#39;nichnoj pnevmonii u pacientov s hronicheskoj obstruktivnoj bolezn&amp;#39;yu legkih [Features of the clinical picture and course of community-acquired pneumonia in patients with chronic obstructive pulmonary disease]. Pul&amp;#39;monologiya, 2: 33&amp;ndash;41.</mixed-citation></ref><ref id="B3"><mixed-citation>3. Bilichenko T.N., Chuchalin A.G. 2018. Zabolevaemost&amp;#39; i smertnost&amp;#39; naseleniya Rossii ot os-tryh respiratornyh virusnyh infekcij, pnevmonii i vakcinoprofilaktika [Morbidity and mortality of the Russian population from acute respiratory viral infections, pneumonia and vaccine prophylaxis]. Tera-pevticheskij arhiv, 1: 22&amp;ndash;26.</mixed-citation></ref><ref id="B4"><mixed-citation>4. Vnebol&amp;#39;nichnaya pnevmoniya: klinicheskie rekomendacii [Community-acquired pneumonia: clinical guidelines]. 2018. 98 s.</mixed-citation></ref><ref id="B5"><mixed-citation>5. Dvoreckij L.I. 2015. Vnebol&amp;#39;nichnaya pnevmoniya u bol&amp;#39;nyh hronicheskoj obstruktiynoj bolezn&amp;#39;yu legkih [Community-acquired pneumonia in patients with chronic obstructive pulmonary dis-ease]. Prakticheskaya pul&amp;#39;monologiya, 2: 17&amp;ndash;24.</mixed-citation></ref><ref id="B6"><mixed-citation>6. Efremova O.A., Kamyshnikova L.A., Sheljakina E.V., Shkiljova I.Ju., Hodosh Je.M., Efimenko E.V. Rol&amp;#39; hronicheskoj obstruktivnoj bolezni ljogkih v razvitii polimorbidnoj patologii [The role of chronic obstructive pulmonary disease in the development of polymorbidity pathology]. Nauchnyj rezul&amp;#39;tat. Medicina i farmacija. 2016. 2. (4): 13&amp;ndash;18.</mixed-citation></ref><ref id="B7"><mixed-citation>7. Ignat&amp;#39;ev V.A., Kiseleva E.A., Zarembo I.A., Cvetkova L.N., Kochergina T.A., Konev V.G., Pendyurin A.K. 2008. Pnevmoniya u pacientov pozhilogo i starcheskogo vozrasta. Some aspects of the development of pneumonia against the background of chronic obstructive pulmonary disease in the elder-ly]. Klinicheskaya gerontologiya, 6: 27&amp;ndash;29.</mixed-citation></ref><ref id="B8"><mixed-citation>8. Korreja L.L., Lebedev T.Yu., Efremova O.A., Proshchaev K.I., Litovchenko E.S. 2013. Problema polimorbidnosti pri sochetanii hronicheskoj obstruktivnoj bolezni legkih i nekotoryh ser-dechno-sosudistyh zabolevanij [The problem of polymorbidity of chronic obstructive pulmonary disease and some cardiovascular diseases]. Nauchnye vedomosti Belgorodskogo gosudarstvennogo universiteta. Seriya: Medicina. Farmaciya. 4: 12&amp;ndash;17.</mixed-citation></ref><ref id="B9"><mixed-citation>9. Kuzubova N.A., Titova O.N., Volchkov V.A., Kozyrev A.G. 2014. Osobennosti vnebol&amp;#39;nich-noj pnevmonii u pacientov s hronicheskoj obstruktivnoj bolezn&amp;#39;yu legkih [Features of community-acquired pneumonia in patients with chronic obstructive pulmonary disease]. Trudnyj pacient, 3: 44&amp;ndash;47.</mixed-citation></ref><ref id="B10"><mixed-citation>10. Chernyaev A.L. 2005. Diagnosticheskie oshibki v pul&amp;#39;monologii [Diagnostic mistakes in pulmonology]. Pul&amp;#39;monologiya, 3: 5&amp;ndash;12.</mixed-citation></ref><ref id="B11"><mixed-citation>11. Chuchalin A.G. 2016. Rossijskoe respiratornoe obshchestvo. Federal&amp;#39;nye klinicheskie rek-omendacii po diagnostike i lecheniyu hronicheskoj obstruktivnoj bolezni legkih [Russian Respiratory So-ciety Federal clinical guidelines for the diagnosis and treatment of chronic obstructive pulmonary dis-ease]. M.: 68</mixed-citation></ref><ref id="B12"><mixed-citation>12. Ewig S., Bauer T., Hasper E., Pizulli L., Kubini R., Luderitz B. 1995. Prognostic analysis and predictive rule for outcome of hospital-treated community-acquired pneumonia. Eur. Respir. J., 8: 392&amp;ndash;397.</mixed-citation></ref><ref id="B13"><mixed-citation>13. Farr B.M., Sloman A.J., Fisch M.J. 1991. Predicting death in patients hospitalized for com-munity acquired pneumonia. Ann. Intern. Med., 115: 428&amp;ndash;436.</mixed-citation></ref><ref id="B14"><mixed-citation>14. GOLD. Global Initiative for chronic obstructive Lung Disease. Global strategy for the diag-nosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Update 2019 // www.goldcopd.com. 15. Groenewegen K.H., Schols A.M., Wouters E.F. 2003. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest., 124 (2): 459&amp;ndash;467.</mixed-citation></ref><ref id="B15"><mixed-citation>16. Huerta A., Crisafulli E., Mene&amp;acute;ndez R., Mart&amp;iacute;nez R., Soler N., Guerrero M., Montull B., Torres A. 2013. Pneumonic and non-pneumonic exacerbations of COPD: inflammatory response and clinical characteristics. Chest., 144: 1134&amp;ndash;1142.</mixed-citation></ref><ref id="B16"><mixed-citation>17. Lieberman D., Gelfer Y., Varshavsky R., Dvoskin B., Leinonen M., Friedman M.G. 2002. Pneumonic vs nonpneumonic acute exacerbations of COPD. Chest., 122(4): 1264&amp;ndash;1270.</mixed-citation></ref><ref id="B17"><mixed-citation>18. Lin S.H., Ji B.C., Shih Y.M., Chen C.H., Chan P.C., Chang Y.J., Lin Y.C., Lin C.H. 2013. Comorbid pulmonary disease and risk of community-acquired pneumonia in COPD patients. Int. J. Tu-berc. Lung Dis., 17: 1638.</mixed-citation></ref><ref id="B18"><mixed-citation>19. Loke Y.K., Kwok C.S., Wong J.M., Sankaran P., Myint P.K. 2013. Chronic obstructive pul-monary disease and mortality from pneumonia: meta-analysis.Int. J. Clin. Pract., 67 (5): 477&amp;ndash;487.</mixed-citation></ref><ref id="B19"><mixed-citation>20. Mannino D.M., Davis K.J., Kiri V.A. 2009. Chronic obstructive pulmonary disease and hos-pitalizations for pneumonia in a US cohort. Respir. Med., 103: 224&amp;ndash;229.</mixed-citation></ref><ref id="B20"><mixed-citation>21. Merino-S&amp;aacute;nchez, Alfageme-Michavila I., Lima-&amp;Aacute;lvarez J. 2005. Prognosis in Patients With Pneumonia and Chronic Obstructive Pulmonary Disease Arch Bronconeumol, 41: 607&amp;ndash;611.</mixed-citation></ref><ref id="B21"><mixed-citation>22. M&amp;uuml;llerova H., Chigbo C., Hagan G.W., Woodhead M.A., Miravitlles M., Davis K.J., Wedzi-cha J.A. 2012. The natural history of communityacquired pneumonia in COPD patients: a population da-tabase analysis. Respir Med, 106: 1124&amp;ndash;33.</mixed-citation></ref><ref id="B22"><mixed-citation>23. Rello J., Rodriguez A., Torres A., Roig J., Sole-Violan J., Garnacho-Montero J., de la Tor-re M.V., Sirvent J.M., Bodi M. 2006. Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur. Respir. J., 27: 1210.</mixed-citation></ref><ref id="B23"><mixed-citation>24. Restrepo M.I., Mortensen E.M., Pugh J.A., Anzueto A. 2006. COPD is associated with in-creased mortality in patients with community-acquired pneumonia. Eur. Respir. J., 28: 346&amp;ndash;351.</mixed-citation></ref><ref id="B24"><mixed-citation>25. Seneff M.G., Wagner D.P., Wagner R.P., Zimmerman J.E., Knaus W.A. 1995. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA, 274: 1852&amp;ndash;1857.</mixed-citation></ref><ref id="B25"><mixed-citation>26. Sibila O. 2014. Prior cardiovascular disease increases long-term mortality in COPD patients with pneumonia. Eur. Respir. J., 43(1): 36&amp;ndash;42.</mixed-citation></ref></ref-list></back></article>